John joins the Trust from Eli Lilly and Company, where he led a team of labs dedicated to identifying new therapies for Alzheimer's disease and schizophrenia.
John said: "I am delighted to have the opportunity to lead the Neuroscience and Mental Health team at the Trust. The Trust has a very strong tradition in this area and this is a time of great opportunity in neuroscience. Understanding the human brain is still one of science's greatest challenges and I'm excited to work with an organisation which is committed funding the most exciting research to help us explore this frontier."
John's scientific interests centre on how abnormal neuronal activity can cause psychiatric and neurological disease. Throughout his career he has been supported by the Wellcome Trust, having been awarded a Senior Research Fellowship, a Career Research Fellowship and Prize Travelling Fellowships.
John has primarily researched the mechanisms behind 'neuronal plasticity', which enables neuronal connections to be strengthened and weakened, depending on their level of activity.
He has worked in in the USA, with Wellcome Trust support. John worked at the National Institute of Neurological Disorders and Stroke for over six years, before returning to England to join Eli Lilly and Company.